Oculis Holding (OCS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.5M

Revenue (quarter)

$383,568.42

Revenue growth (year over year)

+16.66%

Gross profit (trailing twelve months)

$1.5M

Gross margin

100.00%

Net income (trailing twelve months)

−$98.9M

Net income (quarter)

−$12.3M

Net income growth (year over year)

+61.41%

Net margin

−6745.66%

Return on equity

−43.80%

EPS (trailing twelve months)

−$1.72

Book value per share

$4.40

P/E (trailing twelve months)

—

Price to book

1.66

Debt to assets

12.38%

Payout ratio

—

Dividend yield

—

Company profile

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

• Is Oculis Holding (OCS) profitable?

  No. Oculis Holding reported a net loss of $98.9M over the trailing twelve months.

• How much revenue does Oculis Holding (OCS) make?

  Oculis Holding generated $1.5M in revenue over the trailing twelve months, up 16.66% year over year.

• How do I buy stock in Oculis Holding (OCS)?

  OCS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.